Endovascular Treatment for Idiopathic Intracranial Hypertension Improves Clinical Symptoms and Signs

Tratamento endovascular para hipertensão intracraniana idiopática melhora sinais e sintomas clínicos

João Miguel Almeida Silva1 Mario Luiz Marques Conti1 Guilherme Brasileiro Aguiar1 Maurício Jory1 Paulo Helio Monzillo1 José Carlos Esteves Veiga1

1 Faculdade de Ciências Médicas, Santa Casa de São Paulo, São Paulo, SP, Brazil

Abstract

Introduction  New physiopathological concepts regarding idiopathic intracranial hypertension (IIH) recommend the endovascular treatment in refractory patients with transverse sinus stenosis.

Objectives  To assess the role of the transverse sinus stenting treatment in the symptomatology of patients with IIH.

Method  Clinically refractory patients with impaired venous drainage of the transverse sinus were submitted to cerebral angiographies. Patients with pre and poststenotic pressure gradients > 8 mmHg were submitted to endovascular treatment.

Results  Seven patients underwent cerebral angiography with manometry. Stenting was performed in six cases after pressure gradient assessment. All cases showed improvements in headache and resolution of papilledema.

Discussion and Conclusion  Although the role of endovascular therapy should be further studied, our data suggest it may improve the clinical symptoms and signs of IIH in selected patients.

Keywords  ► cerebral angiography ► endovascular procedures ► pseudotumor cerebri

Resumo

Introdução  Novos conceitos fisiopatológicos a respeito da hipertensão intracraniana idiopática (IIH) propõem, em casos refratários, o tratamento endovascular em pacientes com estenose no seio transverso.

Objetivos  Avaliar o efeito do tratamento endovascular, realizado pela implantação de um stent no seio transverso, em pacientes com IIH.

Método  Pacientes refratários clinicamente com alterações da drenagem venosa no seio transverso foram submetidos a angiografia cerebral. Diante de gradientes pressóricos pré e pós-estenóticos maiores do que 8 mmHg, foi feito o tratamento endovascular.
Introduction

Idiopathic intracranial hypertension (IIH) is a rare clinical entity with a series of known symptoms and numerous possible etiologies, which in most cases are unidentified. The historical name for IIH is pseudotumor cerebri, given the symptomatology of elevated intracranial pressure mimicking other conditions, such as brain tumors in the absence of diagnosed brain abnormalities. The first description of intracranial hypertension without an apparent cause was reported by Heinrich Quincke. It was only in 1955 that Foley proposed the name “benign intracranial hypertension” to reflect its clinical course associated with remission and no brain tumors. However, the absence of identifiable etiologies, a situation occurring in up to 90% of cases, and a course often associated with progressive loss of vision, led to the name being changed to idiopathic intracranial hypertension.

Idiopathic intracranial hypertension patients typically present with headaches, visual impairments, pulsatile tinnitus and papilledema. The most prevalent morbidity is progressive visual loss, seen in up to 25% of cases, but it can be rapid in up to 3% of patients. Impairment of the cranial nerves, excluding the optic nerve, can occur in up to 20% of cases. Although IIH is known to predominantly affect overweight women of childbearing age, numerous hypotheses exist to explain the potential mechanisms of the elevated intracranial pressure. As discussed by Walker in 2001, mechanisms involving increased interstitial fluid volume, blood volume, brain tissue volume or cerebrospinal fluid (CSF) production are the most plausible, as are those increasing CSF absorption resistance and elevating cerebral venous pressure. There are other clinical conditions associated with IIH symptoms whose cause-effect relationship are not well established, including vitamin A deficiency and hypervitaminosis A, the use of pharmacological agents (oral retinoids, tetracycline derivatives, indomethacin, lithium, anabolic steroids, tamoxifen), pregnancy, menstrual changes, and systemic diseases (systemic arterial hypertension, diabetes mellitus, thyroid changes, hypoparathyroidism).

Lesions that raise cerebral venous pressure, such as cerebral arteriovenous malformations, thrombosis of the venous sinuses or their occlusion by tumors, are associated with symptoms resembling those of IIH, due to an underlying resistance to CSF absorption. Since the 1990s, studies investigating cerebral venous pressure have been conducted in IIH patients. The results of studies by King and Karahalios further support the theory of obstruction in the cerebral venous outflow. The observation of elevated venous pressures confirmed by manometry during cerebral venography in IIH patients suggests that the occurrence of stenosis of cerebral venous sinuses may be associated with the clinical condition. The results of the study conducted by Farb et al, in which 93% of IIH patients had stenosis of the transverse sinus on magnetic resonance imaging (MRI), lend credence to the notion of obstruction in the cerebral venous outflow.

The most commonly used treatment is acetazolamide, a carbonic anhydrase inhibitor that lowers intracranial and intraocular pressures. Recently, topiramate became an additional option, exhibiting similar effects and good analgesic action, while also favoring weight loss. Surgical management is reserved for refractory patients. A cerebrospinal fluid shunting can be performed to relieve intracranial pressure. Less frequently, fenestration of the optic nerve may be indicated to preserve visual function.

Based on recent physiopathological concepts, stenting in the dural sinus has been recommended in selected cases after detection of pressure variation caused by sinus stenosis. The extent to which intracranial pressure elevation is the cause or consequence of venous sinus stenosis is unclear, but the procedure has gained increasing popularity.

Objectives

To describe the technique and to analyze the clinical outcomes of IIH patients submitted to stenting in the transverse sinus.

Methods

Between 2012 and 2013, 7 patients were referred for diagnostic cerebral angiography with manometry for IIH. Of those 7 patients, 6 met the criteria for transverse sinus stenting, having pressure gradients > 8 mm Hg (Table 1).

The patients were followed by the neurology service and referred for the procedure after confirmation of being clinically refractory with persistent elevated intracranial pressure despite the measures employed.

Out of the six patients submitted to the endovascular treatment, one individual was male, and the remainder, female. Their mean age on the date of the treatment was 39.8 years. The study included patients meeting the diagnostic criteria for IIH, as defined by Friedman & Jacobsen, who recently updated the modified Dandy criteria. The new criteria are more pertinent, following the inclusion of MRI.
findings and additional etiologies for intracranial hypertension, such as cerebral venous thrombosis (→ Table 2).

Lumbar manometry readings were high (> 25 cm H2O) in all 6 patients, with a mean value of 40 cm H2O.

Prior to the procedure, all of the patients were submitted to MR venous angiography. Only those cases showing stenosis of the transverse sinus were submitted to cerebral angiography with manometry. A previous ophthalmologic assessment revealed bilateral optic papilledema in all 6 patients, with a mean value of 40 cm H2O.

Cerebral Venography and Stenting

The patients were assessed previously for renal function and coagulation. During the procedure, the patients were given intravenous systemic anticoagulation with 110 UI/Kg of unfractionated heparin. The patients were placed in the supine position on the fluoroscopy table and given general anesthesia. Cerebral angiography was performed using coaxial arterial catheterization with concomitant venous catheterization, in which the catheter was introduced into the internal jugular vein. The pressure within the venous sinus was measured using a transducer calibrated to the reference of the level of the mid-axillary line.

Stenting was indicated based on pre and post-stenotic gradients > 8 mm Hg, as recommended by Ahmed et al in a similar study involving a representative sample. A self-expanding stent was used and, after it was adequately placed into the stenosis, it was molded according to the length of the stenosis and the diameter of the transverse sinus (→ Fig. 1). Manometry was repeated after stenting.

Antiplatelet therapy with clopidogrel 75 mg daily and aspirin 100 mg daily was used following the procedure. Clopidogrel was withdrawn after the first week. Cranial computed tomographies (CTs) were performed routinely after the procedures to rule out any complications.

### Results

Between 2012 and 2013, 6 patients were submitted to shunting in the transverse sinus as a therapeutic measure for IIH. After the intervention, 3 patients (50%) showed normal lumbar manometry values of < 25 cm H2O, and all had lower

### Table 1 Patients submitted to cerebral angiography for IIH

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age</th>
<th>LP Pre</th>
<th>Post</th>
<th>CN</th>
<th>OD</th>
<th>Gradient</th>
<th>STENT</th>
<th>Outcome</th>
<th>Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-F</td>
<td>28</td>
<td>40</td>
<td>25</td>
<td>V1</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>11</td>
<td>TS R</td>
</tr>
<tr>
<td>2-F</td>
<td>31</td>
<td>48</td>
<td>27</td>
<td>–</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>12</td>
<td>TS R</td>
</tr>
<tr>
<td>3-F</td>
<td>34</td>
<td>36</td>
<td>24</td>
<td>–</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>10</td>
<td>TS R</td>
</tr>
<tr>
<td>4-F</td>
<td>53</td>
<td>38</td>
<td>23</td>
<td>–</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>9</td>
<td>TS R</td>
</tr>
<tr>
<td>5-M</td>
<td>22</td>
<td>30</td>
<td>23</td>
<td>–</td>
<td>–</td>
<td>Clear Borders</td>
<td>Clear Borders</td>
<td>15</td>
<td>TS L</td>
</tr>
<tr>
<td>6-F</td>
<td>30</td>
<td>17–30</td>
<td>–</td>
<td>–</td>
<td>OD Atrophy</td>
<td>OD Atrophy</td>
<td>1</td>
<td>–</td>
<td>Intermittent</td>
</tr>
<tr>
<td>7-F</td>
<td>22</td>
<td>48</td>
<td>26</td>
<td>V1</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>17</td>
<td>TS L</td>
</tr>
</tbody>
</table>

Abbreviations: CN, cranial nerve; F, female; IIH, idiopathic intracranial hypertension; L, left; LP post, post-intervention lumbar puncture manometry (cm H2O); LP pre, pre-intervention lumbar puncture manometry (H2O cm); M, male; OD, optic disc; R, right; TS, transverse sinus.

### Table 2 Diagnostic criteria for IIH established by Friedman & Jacobsen

<table>
<thead>
<tr>
<th>Diagnostic criteria for IIH</th>
<th>Sex</th>
<th>Age</th>
<th>LP Pre</th>
<th>Post</th>
<th>CN</th>
<th>OD</th>
<th>Gradient</th>
<th>STENT</th>
<th>Outcome</th>
<th>Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-In the presence of symptoms, these should only reflect generalized intracranial hypertension or papilledema.</td>
<td>1-F</td>
<td>28</td>
<td>40</td>
<td>25</td>
<td>V1</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>11</td>
<td>TS R</td>
</tr>
<tr>
<td>2-In the presence of signs, these should only reflect generalized intracranial hypertension or papilledema.</td>
<td>2-F</td>
<td>31</td>
<td>48</td>
<td>27</td>
<td>–</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>12</td>
<td>TS R</td>
</tr>
<tr>
<td>3–Documented intracranial hypertension, as measured by lumbar puncture with the patient in lateral decubitus (pressures &gt; 20 cm H2O in normal-weight individuals, and &gt; 25 cm H2O in obese individuals are considered abnormal).</td>
<td>3-F</td>
<td>34</td>
<td>36</td>
<td>24</td>
<td>–</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>10</td>
<td>TS R</td>
</tr>
<tr>
<td>4-Normal CSF composition.</td>
<td>4-F</td>
<td>53</td>
<td>38</td>
<td>23</td>
<td>–</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>9</td>
<td>TS R</td>
</tr>
<tr>
<td>5–Absence of evidence of hydrocephaly, structural lesions, with mass or vascular effect on MRI or CT, with contrast for typical patients, and with complementation using venous MR angiography for other patients.</td>
<td>5-M</td>
<td>22</td>
<td>30</td>
<td>23</td>
<td>–</td>
<td>–</td>
<td>Clear Borders</td>
<td>Clear Borders</td>
<td>15</td>
<td>TS L</td>
</tr>
<tr>
<td>6-Absence of other causes of intracranial hypertension identified.</td>
<td>6-F</td>
<td>30</td>
<td>17–30</td>
<td>–</td>
<td>–</td>
<td>OD Atrophy</td>
<td>OD Atrophy</td>
<td>1</td>
<td>–</td>
<td>Intermittent</td>
</tr>
<tr>
<td>7-F</td>
<td>22</td>
<td>48</td>
<td>26</td>
<td>V1</td>
<td>–</td>
<td>Papilledema</td>
<td>Clear Borders</td>
<td>17</td>
<td>TS L</td>
<td>Asymptomatic/transient headache</td>
</tr>
</tbody>
</table>

Abbreviation: CSF cerebrospinal fluid; CT, computed tomography; IIH, idiopathic intracranial hypertension; MRI, magnetic resonance imaging.

Note: Adapted from Friedman & Jacobsen.20
Patient referral sequence

IIH Diagnosis  
Friedman & Jacobsen criteria \(^{20}\)  
Clinically refractory  
Headache Clinic  
Acetazolamide / Topiramate  
Venous MR angio  
TS stenosis  
No TS stenosis  
Digital Angiography  
Assessment for surgical treatment  
Gradient > 8mmHg  
Gradient < 8mmHg  
TS Stent

**Fig. 1** Flowchart of the clinical investigation and treatment of IIH patients.

**Fig. 2** (A) Pre-procedure cerebral venography showing the stenosis in the transition between the transverse and sigmoid sinuses. (B) Post-procedure cerebral venography showing the improvement of the stenosis after the stent placement. (C) Stent after implantation in the transverse sinus.
lumbar manometry values, with a post-intervention mean of 24.7 cm H₂O. The mean reduction in lumbar manometry value after the procedure was 15.3 cm H₂O. One patient (patient 6) did not meet the criteria for transverse sinus stenting, having pressure gradients < 8 mm Hg. This patient showed an intermittent evolution, with a fluctuating course of signs and symptoms.

After the intervention, five patients showed an improvement on the fundoscopy exam, with clear optic discs. The assessment testing for impairment of the other cranial nerves led to the identification of two patients with impaired function of the abducens nerve prior to the procedure, which evolved with clinical improvement post intervention.

With regard to the pressure gradient between the proximal and distal limits to the transverse sinus stenosis, a pre-intervention mean of 12.3 mm Hg was observed. The post-intervention mean was 1.7 mm Hg, thus representing an average reduction of 10.6 mm Hg. The treatment target was the right transverse sinus in four cases, and the left transverse sinus in the remaining two patients. Two individuals (patients 2 and 3) had transverse sinus stenosis that met the criteria for bilateral stenting. In these cases, the side with the highest gradient was the target of the treatment.

Concerning the post-intervention clinical status, both patients showed improvements in their headaches. Four patients became asymptomatic (66.7%), while the remaining 2 showed improvement but not full resolution of the headache (33.3%). The improvement began within 24 hours of the procedure in these patients. In the first month, two of the asymptomatic patients (patients 4 and 7) had complaints of pulsatile headache, albeit at a lower intensity than before, located retro auricular and ipsilateral to the stented side. This symptom resolved spontaneously during the out-patient follow-up.

**Discussion**

Stenosis in the transition between the transverse and sigmoid sinuses is frequently observed in patients with IIH. Studies employing the use of venous MR angiography for diagnosis have revealed a greater prevalence of this condition among individuals with IIH compared with a control group of healthy individuals. Farb et al detected venous stenosis bilaterally in 27 out of 29 IIH patients, and found the same abnormality in only 4 of the 59 patients from the control group. The observation of elevated pressure within the cerebral venous sinuses of these cases is consistent with the notion that a partial blockage of the cerebral venous drainage could play a key role in the physiology of the disease. However, refractory cases eligible for endovascular treatment are infrequent, and this fact justifies our small sample size, common to other studies about this topic.

Secondary intracranial hypertension has an underlying medical cause. In many situations, elevated venous pressure can be the physiological mechanism involved, as it occurs in dural venous fistulas, cerebral venous thrombosis of the sinuses or venous sinus compression. However, in the majority of IIH cases, cerebral angiography shows a narrowing of the transverse sinus, which does not reflect acute venous thrombosis. A pivotal question regarding transverse sinus stenosis in IIH is whether this abnormality is the cause or consequence of the elevated intracranial pressure. Mathematical models support the hypothesis that the transverse sinus is a compliant structure to the point of being vulnerable to extrinsic compression, which may obstruct the venous drainage, resulting in venous and intracranial hypertension.

On the other hand, results published in recent years, which show clinical improvement in some patients after the reconstruction of the transverse sinus with endovascular stents, reinforce the hypothesis that the stenosis established in the sinus independently causes the venous flow blockage. These two alternatives may give rise to similar symptomatology, alone or concomitantly, explaining the variability in outcomes seen on the clinical assessment of patients.

The present study findings are consistent with the growing body of evidence on the endovascular option for the treatment of IIH. The first report of IIH treatment with the use of stents was published by Higgins et al in 2002, and it involved a 30-year-old woman with a 22-month prior history of headache, papilledema and transverse sinus stenosis visualized on venous MR angiography. Dilation was achieved by stenting, resulting in a reduced pressure gradient and improvement in symptoms. Based on this data, a growing number of studies investigating this topic have been conducted, in which the vast majority of patients were women. In a recent review, a group of Canadian researchers reviewed 8 studies and analyzed a total of 40 patients treated using the method. After stenting, 82.5% of the patients showed resolution or significant improvement of their headaches, and 91% of individuals exhibiting papilledema upon admission showed an improvement of this sign. Akin to the present investigation, headache ipsilateral to the stent occurred, an event observed in over 50% of the patients, and characterized as transient in most cases. Ahmed et al attributed this symptom to the distension of the transverse sinus after the procedure, and it generally improved after one week. This hypothesis can explain the transience of symptoms presented by patients 4 and 7.

The analysis of the situation of some patients with bilateral stenosis and high pressure gradients on both sides reveals differences in approach. In the present study, we decided to perform the procedure on one sinus only, electing the side with the highest pressure gradient. The rationale for this conduct is grounded in the pro-thrombotic properties of stents, in which a unilateral approach precludes the risk for the patient of future bilateral thrombosis of the transverse sinuses. Higgins, in 2003, and Donnet, in 2008, reported bilateral stenting of the transverse sinus in two cases and one case respectively. Up to the date of the publication of the studies, no thrombosis was reported during the follow-up of these patients.

Endovascular therapy with the use of stents carries an inherent risk associated with serious complications, such as perforation of vessels, migration of the prosthesis, increased risk of thrombosis, and restenosis of the implantation site. Due to these risks, anticoagulation during the procedure and antiplatelet therapy after the intervention are necessary, with no consensus on the minimum duration of the antiplatelet therapy. In the present study, no post-intervention
complications were seen, although studies involving larger samples have observed complications. Ahmed,²¹ in a study involving 52 patients, observed the emergence of a neurological deficit after the intervention, secondary to an acute subdural hematoma and subarachnoid hemorrhage. Allergic reactions to acetylsalicylic acid and clopidogrel have also been observed in another two patients.²¹

The assessment of the response to the endovascular treatment for IIH is hard to interpret.²⁶ The present study included only six cases in which stents were effectively implanted. In addition, the clinical course of IIH is highly variable, having a subacute or intermittent course.⁴ Another factor to take into account is the durability of the clinical improvement, in which a longer follow-up period is required for a more meaningful assessment. Evidence is needed from a randomized study that could exclude confounding variables such as weight loss, which can have a major influence on the clinical improvement of some patients.⁴,⁶

**Conclusion**

Patients refractory to clinical treatment must be submitted to the adequate imaging investigation. Angiography should be performed only after the detection of a transverse sinus stenosis on an MRI with venous study.

In cases of elevated pressure gradients, the endovascular therapy can promote a significant improvement in the symptoms of patients with IIH. However, the efficacy and safety of this procedure should be assessed by randomized studies involving larger samples.

**References**